Zithromax (azithromycin): FDA Statement on risk of cardiovascular death

Thursday, May 17, 2012 1:45:00 PM CST

A retrospective cohort study reports small increase in risk of cardiovascular deaths and risk of all cause deaths associated with 5 day course of antibiotic drug [...] Read More..

Gilenya (fingolimod): Drug Safety Communication - Safety Review of a Reported Death After the First Dose

Monday, May 14, 2012 12:30:00 PM CST

UPDATED 05/14/2012. New recommendations for monitoring patients, and new contraindications, and dosing & administration information for use in certain patients. [...] Read More..

Hydromorphone Hydrochloride Injection 1 MG/ML, (C-II) 1 ML Fill In 2.5 ML Carpuject: Recall - May Contain More Than the Intended Fill Volume

Monday, May 14, 2012 12:05:00 PM CST

An overdose of Hydromorphone may result in life-threatening consequences, including respiratory depression (slowed breathing or suspension of breathing), low blood pressure, and reduced heart rate including circulatory collapse. [...] Read More..

Revlimid (lenalidomide): Ongoing Safety Review - Increased Risk of Developing New Malignancies

Monday, May 07, 2012 12:20:00 PM CST

UPDATED 05/07/2012. Increased risk of developing acute myelogenous leukemia, myelodysplastic syndromes, and Hodgkin lymphoma in patients being treated with Revlimid. [...] Read More..

Certain Compounded Drugs from Franck's: FDA Issues Second Warning to Physicians

Friday, May 04, 2012 10:00:00 AM CST

[UPDATED 05/04/2012] The Centers for Disease Control and Prevention (CDC) has advised healthcare personnel to avoid use of compounded products labeled as sterile from Franck’s during the ongoing investigation. [...] Read More..

Victrelis (boceprevir) and Ritonavir-Boosted Human Immunodeficiency Virus (HIV) Protease Inhibitor Drugs: Drug Safety Communication - Drug Interactions

Thursday, April 26, 2012 1:45:00 PM CST

UPDATED 04/26/2012. Label revised to state that co-administration of Victrelis with certain ritonavir-boosted human immunodeficiency virus protease inhibitors is not recommended. Originally posted 02/09/2012 [...] Read More..

X-Rock: Recall - Undeclared Drug Ingredient

Wednesday, April 25, 2012 7:50:00 AM CST

Undeclared active ingredients may interact with nitrates found in some prescription drugs (such as nitroglycerin) and lower blood pressure to dangerous levels. [...] Read More..

Roche Diagnostics Operations Elecsys Troponin I and Elecsys Troponin I STAT Immunoassays: Recall – Doctors may receive a falsely low result

Tuesday, April 24, 2012 11:15:00 AM CST

Customers should immediately discontinue use of any affected product. [...] Read More..

Brilliant Blue G Compounded by Franck's: Recall of Unapproved Drug - Ongoing Investigation of Fungal Endophthalmitis Cases

Friday, April 20, 2012 12:00:00 PM CST

[UPDATED 05/04/2012] The Centers for Disease Control and Prevention (CDC) has advised healthcare personnel to avoid use of compounded products labeled as sterile from Franck’s during the ongoing investigation. [...] Read More..

Aliskiren-containing Medications: Drug Safety Comunication - New Warning and Contraindication

Friday, April 20, 2012 10:38:00 AM CST

Risk of renal impairment, hypotension, and hyperkalemia with concomitant use of aliskiren with angiotensin receptor blockers (ARBs) or angiotensin converting enzyme inhibitors (ACEIs) in patients with diabetes. [...] Read More..

Other‐Sonic Generic Ultrasound Transmission Gel: Safety Communication - Risk of Bacterial Contamination

Wednesday, April 18, 2012 12:30:00 PM CST

Exposure to contaminated product may lead to serious infections. [...] Read More..

Morphine Sulfate Injection USP, 4 mg/mL (C-II), 1 mL fill in 2.5 mL Carpuject by Hospira, Inc: Recall - May Contain More Than Intended Fill Volume

Wednesday, April 18, 2012 8:00:00 AM CST

Consequences of opioid pain medication overdose can be life-threatening, including respiratory depression (slowed breathing or suspension of breathing), and low blood pressure. [...] Read More..